Ann Richmond

Vanderbilt University honored 32 retiring faculty members on May 9 for their years of service by bestowing upon them the title of emerita or emeritus faculty during Vanderbilt’s Commencement ceremony at GEODIS Park. Two outgoing deans also were recognized for service to the university. Read More

Kevin Murphy, Andrew W. Mellon Chair in the Humanities and professor of history of art and architecture, and Mary Anne Hunting, BA’80, have uncovered the histories of female architects in the American Modernism period of the U.S. in new research. Read More

A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma. Read More

While 60 percent of people with metastatic melanoma, an aggressive type of skin cancer, have multiple treatment options available to them, roughly 40 percent either do not respond to treatment, or relapse. Read More

A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients. Read More

The 3rd National Veterans Health Affairs Research Conference held at Vanderbilt University Medical Center May 17-18. Read More

Vanderbilt University cancer researcher Ann Richmond, Ph.D., 2016 recipient of one of the highest honors for scientific achievement bestowed by the U.S. Department of Veterans Affairs, will be a keynote speaker during a national VA research conference next week at Vanderbilt University School of Medicine. Read More

Ordinary cells can be transformed into cancer cells through epigenetics — changes to DNA that turn genes on or off. Those gene changes can protect cells or make them vulnerable to disease processes including cancer. Read More

Leading cancer investigators from several prominent universities and laboratories will headline the 2017 Vanderbilt-Ingram Cancer Center Annual Scientific Retreat, to be held Thursday, May 4. Read More

Vanderbilt University cancer researcher Ann Richmond, Ph.D., has won the 2016 William S. Middleton Award, the highest honor for scientific achievement bestowed by the Biomedical Laboratory Research and Development Service of the U.S. Department of Veterans Affairs (VA). Read More

Combining therapies for melanoma that induce cell senescence and that activate the immune response may improve outcomes for patients. Read More

Efforts to enable the immune system to “see” the cancer and attack the aberrant cells were the prime focus during Vanderbilt-Ingram Cancer Center’s Annual Retreat, held April 30 at the Vanderbilt University Student Life Center. Read More

Melanoma is the most lethal form of skin cancer, with high mortality rates. While new drugs have been approved to treat the disease, patients nearly always develop resistance to the therapies and the cancer advances. Read More

The activity of a certain factor in immune cells is essential for an anti-tumor response, emphasizing the need to consider the effects of anti-cancer therapies on immune cells. Read More

The role of inflammation in gastrointestinal cancer development was a prominent theme among guest speakers during the Vanderbilt-Ingram Cancer Center annual retreat held at the Vanderbilt Student Life Center. Read More

Several Vanderbilt researchers have collaborated with this year's Nobel Chemistry winners. Read More

New therapeutic target for angiosarcoma – an aggressive, highly fatal tumor of the blood vessels – identified. Read More

An experimental melanoma drug may be beneficial for patients not eligible for targeted therapies. Read More